This broadcast replay from AACE 2026 features an interactive, case-based Q-Challenge format focused on acromegaly. Participants engage with clinical scenarios designed to assess and reinforce diagnostic evaluation and treatment decision-making. The activity highlights key considerations in identifying acromegaly, interpreting clinical findings, and selecting appropriate management strategies based on patient presentation. Through guided questions and expert-informed discussion, learners gain insight into the real-world application of evidence-based approaches.

Bronchiectasis is a chronic, progressive respiratory disease that is characterized by accelerated lung function decline and impaired quality of life, yet it remains substantially under recognized and underdiagnosed in routine practice. High-resolution computed tomography is the cornerstone of diagnosis, but early and subtle radiologic manifestations are frequently overlooked or misattributed to aging, infection, or nonspecific small airway disease. Radiologists occupy a pivotal position as the earliest decision-makers in the bronchiectasis care pathway, so it is imperative that they can identify bronchiectasis accurately and early to ensure timely referral to specialized care for evidence-based therapy.

This 15-minute online CME activity reviews the clinical implications of the updated NCCN Guidelines for advanced urothelial carcinoma (aUC), with a focus on evolving first-line and subsequent treatment strategies. The program highlights the shift away from cisplatin eligibility as the primary determinant of frontline therapy selection and examines key clinical trial data that inform current practice. Participants will explore sequencing considerations following frontline therapy as well as the role of biomarker-directed therapies in later lines of care. The activity also emphasizes early recognition and management of treatment-related adverse events alongside strategies for dose modification and supportive care. Multidisciplinary coordination and shared decision-making are discussed as essential components of optimizing patient-centered care in aUC.

Dr. Kathleen Moore reviews the clinical significance of HER2 expression across diverse solid tumors and its role in guiding treatment decisions. She outlines HER2 testing methodologies, including immunohistochemistry (IHC), to identify patients with advanced solid tumors who may benefit from HER2-targeted antibody–drug conjugates (ADCs). Dr. Moore summarizes key data from trials such as DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02 that supported tumor-agnostic approval of trastuzumab deruxtecan (T-DXd) for previously treated metastatic HER2-positive (IHC 3+) solid tumors, along with strategies for proactive monitoring and management of ADC-associated adverse events.

This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.

This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.

This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.

This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.

This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.

Drs. Neeraj Agarwal and Rana McKay discuss treatment intensification strategies in metastatic castration-sensitive prostate cancer (mCSPC), with a focus on combining androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPIs) and chemotherapy. They review key clinical trial data supporting doublet and triplet regimens that improve overall survival and other clinically meaningful outcomes. The faculty examine how disease burden, metastatic pattern, genomic features, comorbidities, and patient fitness inform selection of doublet versus triplet therapy. They also highlight multidisciplinary approaches to managing treatment-related adverse events and preserving quality of life in patients receiving intensified treatment.